Efficacy of Dapagliflozin & Metformin Vs Sitagliptin & Metformin in New patients with Type 2 Diabetic in HMC Hospital Peshawar
DOI:
https://doi.org/10.47672/ajhmn.916Keywords:
Efficacy, Dapagliflozin, Metformin, Sitagliptin, Type 2 Diabetes Mellitus, Hmc HospitalAbstract
Background: Efficacy of Dapagliflozin in combination with Metformin versus Sitagliptin in type 2 diabetic patients in hayat abad medical complex hospital Peshawar to check the efficacy of these anti Diabetic drug on patients and check the results of these two double combination drug using long tram and short tram treatment check effectiveness, safety side effects.
Purpose: Randomized Measured study in Department of diabetes and Endocrinology HMC Hospital, Peshawar after the hospital ethical committee approval for one year i.e. 12-11-2017 to 12-12-2018 check the efficy of dapagliflozin in combination with metformin versus sitagliptin local setting.
Methodology: three hundred subjects were selected via Hospital and opd, Patients were randomly divided into two groups. In Group-A, patients were given 100mg q.d sitagliptin plus 850 mg metformin twice a day. In Group-B, patients were given 10mg qd dapagliflozin plus 850mg metformin twice a day. Patients were followed up in OPD for 7/24 weeks. After 7/24 weeks, blood sample was obtained for assessment of HbA1c. Reports were measured and if HbA1c is < 6.0 then efficacy achieved. All this information was recorded on Performa.
Results: the efficacy dapagliflozin and metformin versus sitagliptin and metformin in type 2 diabetes mellitus patients shows that 105(35.5% in Group A and 81(25.5%) in Group-B had efficacy and p value was 0.10.
Conclusion: the study showed that Role of Efficacy of Metformin and Dapagliflozin is not significantly different when compared with Metformin and Sitagliptin in Diabetes Mellitus Type 2 patients.
Downloads
References
Cahn A, Cefalu WT. Clinical considerations for use of initial combination therapy in type 2 diabetes. Diabetes Care. 2016;39(suppl 2):S137–S145. - PMC - PubMed
Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372(23):2197–2206. - PubMed
Gerstein HC, Miller ME, Ismail-Beigi F, et al. ACCORD Study Group Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet. 2014;384(9958):1936–1941. - PMC - PubMed
ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;2008(358):2560–2572. - PubMed
Ismail-Beigi F, Craven T, Banerji MA, et al. ACCORD Trial Group Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetesanalysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430. - PMC - PubMed
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. - PubMed
Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–314. - PMC - PubMed
American Diabetes Association Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033–1046. - PMC - PubMed
Egede LE, Gebregziabher M, Dismuke CE, et al. Medication nonadherence in diabetes longitudinal effects on costs and potential cost savings from improvement. Diabetes Care. 2012;35:2533–2539. - PMC - PubMed
Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–1224. - PubMed
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):1140–1149. - PubMed
Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27(2):384–391. - PubMed
Jha AK, Aubert RE, Yao J, Teagarden JR, Epstein RS. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff (Millwood) 2012;31(8):1836–1846. - PubMed
Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm. 2009;66(16):1471–1477. - PubMed
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719. - PubMed
Balu S, Simko RJ, Quimbo RM, Cziraky MJ. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin. 2009;25(11):2765–2775. - PubMed
Hussein MA, Chapman RH, Benner JS, et al. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrollees? A non-randomized, observational, retrospective study. Am J Cardiovasc Drugs. 2010;10(3):193–202. - PubMed
Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62(1):76–87. - PMC - PubMed
Jarab AS, Almrayat R, Alqudah S, et al. Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes. Int J Clin Pharm. 2014;36(4):725–733. - PubMed
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Muhammad Hussain Afridi, Muhamamd Naeem Khan, Atta Muhammad Khan, Muhammad Abbass, Qazi Ikram, Javaid Hassan, Khadija Bibi, Shah Zaib
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
